Expertise in
24
conditions

Dr. Matthew M. Heeney

Hematology | Oncology
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 
Accepting New Patients
Expertise in
24
conditions
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 

Overview

Matthew Heeney is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Heeney is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

He is actively involved in clinical research, co-authoring 75 peer reviewed articles and participating in 4 clinical trials. Dr. Heeney is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in MA

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Dana-farber Cancer Institute
450 Brookline Ave, Boston, MA 02215

Additional Areas of Focus

Dr. Heeney has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease
Enrollment Status: Unknown
Publish Date: January 31, 2019
Intervention Type: Drug
Study Drug: Docosahexanoic Acid (DHA)
Study Phase: Phase 2
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Enrollment Status: Completed
Publish Date: February 07, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

75 Total Publications

Prevention, Screening, Diagnosis, and Treatment of Iron Deficiency and Iron Deficiency Anemia in Infants, Children, and Adolescents: Clinical Report.
Prevention, Screening, Diagnosis, and Treatment of Iron Deficiency and Iron Deficiency Anemia in Infants, Children, and Adolescents: Clinical Report.
Journal: Pediatrics
Published: June 21, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
18
conditions
Dr. Akiko Shimamura
Hematology | Oncology
Expertise in
18
conditions
Dr. Akiko Shimamura
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Akiko Shimamura is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Shimamura is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Shwachman-Diamond Syndrome, Aplastic Anemia, Agranulocytosis, Severe Congenital Neutropenia, and Bone Marrow Transplant. Dr. Shimamura is currently accepting new patients.

Expertise in
23
conditions
Dr. Katherine A. Janeway
Hematology | Oncology
Expertise in
23
conditions
Dr. Katherine A. Janeway
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Katherine Janeway is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Janeway is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Neuroepithelioma, and Bone Marrow Aspiration. Dr. Janeway is currently accepting new patients.

Frequently Asked Questions about Dr. Matthew M. Heeney

How do I make an appointment with Dr. Matthew M. Heeney?

You can book an appointment with Dr. Matthew M. Heeney by calling their office at 877-442-3324. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthew M. Heeney a top-rated expert for Sickle Cell Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew M. Heeney is classified as an Elite expert for Sickle Cell Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew M. Heeney specialize in?

While Dr. Matthew M. Heeney is a Hematology, they have specific expertise in Sickle Cell Disease, Congenital Hemolytic Anemia, and Hemolytic Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Matthew M. Heeney participate in research or clinical trials?

Yes. Dr. Matthew M. Heeney has published 75 articles and abstracts on conditions like Sickle Cell Disease. You can view a list of Dr. Matthew M. Heeney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew M. Heeney accept my insurance?

Dr. Matthew M. Heeney accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 877-442-3324 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heeney's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile